Prior authorization denials for step therapy: how formulary exceptions, clinical documentation, and appeal deadlines determine reconsideration
KFF’s analysis of available 2025 prior authorization data found insurers denied at least 1 in 8 standard prior authorization requests across Medicare Advantage, Medicaid managed care, and the federally facilitated ACA Marketplace. That’s the backdrop. When a denial involves step therapy, billing teams often treat reconsideration as a resubmission problem instead of a documentation problem. Simply showing that the drug or test was ordered usually isn’t enough. The record has to explain why the plan’s preferred sequence does not fit the patient and do so within the payer’s deadline framework.
Step therapy denials usually turn on the exception request, not the original order
Step therapy denials are formulary management denials with a clinical overlay. The payer is saying, in effect, “use the preferred option first unless you can justify an exception.” If the reconsideration packet does not answer that directly, it is just a stack of paperwork.
The source packet does not provide payer-specific step therapy rules for UnitedHealthcare, Aetna, Cigna, or Anthem, so do not invent them in the workflow. It does support the broader point that payer coverage policies can classify services in ways that block coverage unless the record clearly supports medical necessity. MedLearn’s August 2026 laboratory guidance on PLA code 0529U offers a clear example. It states that many payer coverage policies assign PLA codes experimental or investigational status, which can exclude coverage because of a lack of literature establishing clinical efficacy, safety, or applicability to clinical practice. It also states that laboratories may need to submit medical record documentation substantiating medical indications and supporting medical necessity.
That same operational rule applies to step therapy reconsiderations. The appeal has to address the reason for noncoverage. When the denial says “preferred product not tried,” the exception request needs to document why the preferred sequence is clinically inappropriate. Restating the diagnosis or attaching the order does not do that. When the denial says “insufficient support for intended use,” the chart has to show how the service or product will direct treatment decisions.
Clinical documentation must link the denied item to treatment decisions
This is where teams lose ground. They send generic chart notes, medication lists, and a fax cover sheet marked “urgent reconsideration.” The packet points to a much tighter standard.
According to MedLearn and RACmonitor, when seeking prior authorization or appealing a denied claim for 0529U, it is beneficial to present chart notes supporting the intended use of results in directing treatment decisions, such as guiding anticoagulant duration after a clot or informing hormone use. The same article says documentation can indicate a strong family history or specific high-risk situations, including planning pregnancy, using estrogen or oral contraceptives, or undergoing major surgery.
For a step therapy denial, build the reconsideration record the same way. Do not dump the entire chart. Pull the portions that establish medical necessity and intended use. The record should make clear why the plan’s step requirement does not fit the patient’s clinical circumstances and what decision the requested therapy will drive. If prior options are not appropriate, the documentation needs to say so plainly. If the issue is risk, contraindication, or a treatment decision that hinges on the denied service, the chart notes need to bring that forward so a utilization reviewer cannot miss it.
Coding still matters. When a service is reported with a code like 0529U, the code itself does not carry the medical necessity argument. The diagnosis coding and clinical note do that work together. If the payer’s denial language refers to experimental or investigational status, the reconsideration should address that status assignment with the documentation the policy permits, rather than a generic billing appeal letter.
Formulary exceptions depend on answering the payer’s actual denial reason
“Formulary exception” does not mean “please make an exception.” Operationally, those are different things. A real exception request maps directly to the denial logic.
MedLearn does not outline a step therapy drug policy in the packet. It does show the structure payers use when they question coverage. The service is either excluded under a policy classification, or the payer is looking for chart-level proof of medical indications and medical necessity. That framework applies to pharmacy and medical prior authorization teams.
When the denial rests on a coverage classification, the reconsideration should identify the clinical facts the payer’s policy says matter. When it rests on missing support, close that record gap quickly. If the denial letter does not make the distinction clear, stop and clarify before submitting an appeal that misses the point.
- Match the denial category. Is it step edit not met, investigational status, or insufficient medical necessity support?
- Submit only the records that answer that category. Focused chart notes beat bloated attachments.
- Tie the request to treatment direction. Show what decision depends on approval.
- Route by deadline. Reconsideration timing belongs in the work queue, not in someone’s inbox.
That last point matters more than teams admit. A strong clinical argument filed after the appeal window closes is still a dead appeal. The source packet does not provide payer-specific appeal deadlines, so do not assign hard day counts unless the plan document says so. Appeal and reconsideration windows are plan-governed and operationally decisive. Every denial should be logged the day it arrives, categorized by reason, and routed with the filing deadline visible to billing and clinical staff.
Appeal timing belongs to revenue cycle control, not utilization management alone
The clinical team writes the note. Billing determines whether the organization gets that note attached and filed on time. That is where denials sit and rot.
The packet also includes AAPC’s report that hospital outpatient departments demonstrating compliance with Medicare coverage, coding, and payment rules related to prior authorization are eligible for an exemption assessed yearly and remaining in effect for a 12-month period. The context is different, but the lesson is the same. Payers and programs reward clean prior authorization operations and scrutinize weak ones. Disciplined workflows reduce rework. Sloppy ones turn reconsiderations into a scavenger hunt.
KFF’s finding on 2025 denial activity should end any internal debate about whether these are edge cases. They are not. Prior authorization denials are common enough to require a real reconsideration standard. Denial intake, reason-code mapping, chart abstraction, and deadline tracking need to connect. When the prior authorization team, pharmacy team, and billing office each keep separate spreadsheets, delay is already built in.
Monday morning, implement one rule: every step therapy or formulary-based denial gets a standardized reconsideration checklist with three required fields before it can leave the queue, denial reason category, chart note showing intended treatment impact, and the payer filing deadline. If one is missing, do not submit it yet. One checklist. One queue.